A number of clinical trials reveal that new direct-acting antiviral agents (DAAs) are showing promise in treatment of hepatitis C according to data presented at the International Liver Congress 2013. The following covers key results from the much anticipated Phase III trials conducted among HCV patients with a range of genotypes (GT 1 to 6) on DAA treatment. POSITRONulliA study of interferon (IFN)-ineligible, IFN-intolerant, or IFN-unwilling ...
via Medindia Health News More READ
No comments:
Post a Comment